Back to Biosimilar Integration:Administration’s Considerations
Biosimilar Integration:Administration’s Considerations

Biosimilar Integration:Administration’s Considerations

Speaker

Philip Schwieterman, PharmD MHA

Philip Schwieterman obtained his bachelors and doctorate of pharmacy degrees from The Ohio State University and his Master of Health Administration from the University of Kentucky. Philip joined UK HealthCare as a Pharmacy Director in 2013 where he has led numerous financial, clinical, and operational initiatives surrounding the growth and oversight of oncology, infusion, specialty and pediatric pharmacy services. He currently serves as the Pharmacy Director for Oncology and Pediatrics.

Product Details

Statement of Need/Activity Purpose

This webinar will review the numerous financial, operational, and clinical aspects to consider when implementing biosimilars into oncology care.

Learning Objectives

  • Review the approval and commercialization process of biosimilar medication
  • Examine biosimilar’s impact on marketplace trends
  • Review various financial, operational, and clinical considerations for the use of biosimilars
  • Present methods to successfully incorporate biosimilars into oncology workflow
  • List Price: Free